Stocks
REGENXBIO Inc.RGNX
NASDAQHealthcareBiotechnology$8.57-5.62%
Price as of · delayed, not real-time
Specializing in gene therapy, this biotech firm develops and commercializes recombinant adeno-associated virus (AAV) gene delivery platforms. Investors monitor its pipeline of treatments for rare diseases and partnerships with larger pharmaceutical companies.
Market Cap: $442.3M52W Range: $5.04 – $16.19
Congressional Interest in REGENXBIO Inc. (RGNX)
4 members of Congress have disclosed 5 trades in REGENXBIO Inc. (RGNX), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
4
Buys
3
Sells
2
Who in Congress Is Trading RGNX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-09-08 | Rohit Khanna | buy | $1K – $15K |
| 2019-11-08 | PETER WELCH | sell | $1K – $15K |
| 2019-10-22 | PETER WELCH | buy | $1K – $15K |
| 2017-06-01 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2015-09-30 | JAMES B. RENACCI | buy | $1K – $15K |